Cytotoxic effects of müllerian inhibiting substance (MIS)? 1988

J P Janssens, and V Noto, and G van Tendeloo, and J Bonte, and W de Loecker
Department of Gynecological Oncology, University of Leuven, Belgium.

To determine whether Müllerian Inhibiting Substance (MIS) is the factor responsible for the cytotoxic effects of testicular preparations on gynecological cancers, homogenates of bovine fetal testes were fractionated by Sephadex G 200 chromatography and their cytotoxic effects tested on a Müllerian-derived endometrial cancer cell line (AN3-CA), an ovarian carcinoma cell line (CAOV 3) and on a breast cancer cell line (MCF 7). No difference in cytotoxicity was found between Müllerian and non-Müllerian derived human cancer cells. Cytotoxicity and MIS activity were found in different fractions on Sephadex G 200 gel chromatography.

UI MeSH Term Description Entries
D009095 Mullerian Ducts A pair of ducts near the WOLFFIAN DUCTS in a developing embryo. In the male embryo, they degenerate with the appearance of testicular ANTI-MULLERIAN HORMONE. In the absence of anti-mullerian hormone, mullerian ducts give rise to the female reproductive tract, including the OVIDUCTS; UTERUS; CERVIX; and VAGINA. Muellerian Duct,Mullerian Duct,Muellerian Ducts,Duct, Muellerian,Duct, Mullerian,Ducts, Muellerian,Ducts, Mullerian
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D005260 Female Females
D005833 Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE). Gynecologic Neoplasms,Female Genital Neoplasms,Neoplasms, Female Genital,Neoplasms, Gynecologic,Female Genital Neoplasm,Genital Neoplasm, Female,Gynecologic Neoplasm,Neoplasm, Female Genital,Neoplasm, Gynecologic
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006131 Growth Inhibitors Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth ( Cell Growth Inhibitor,Cell Growth Inhibitors,Growth Inhibitor,Growth Inhibitor, Cell,Growth Inhibitors, Cell,Inhibitor, Cell Growth,Inhibitor, Growth,Inhibitors, Cell Growth,Inhibitors, Growth
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013735 Testicular Hormones Hormones produced in the testis. Hormones, Testicular

Related Publications

J P Janssens, and V Noto, and G van Tendeloo, and J Bonte, and W de Loecker
October 1989, Proceedings of the National Science Council, Republic of China. Part B, Life sciences,
J P Janssens, and V Noto, and G van Tendeloo, and J Bonte, and W de Loecker
June 1995, The Journal of pathology,
J P Janssens, and V Noto, and G van Tendeloo, and J Bonte, and W de Loecker
October 1993, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
J P Janssens, and V Noto, and G van Tendeloo, and J Bonte, and W de Loecker
January 2021, Journal of Cancer,
J P Janssens, and V Noto, and G van Tendeloo, and J Bonte, and W de Loecker
June 2012, International journal of oncology,
J P Janssens, and V Noto, and G van Tendeloo, and J Bonte, and W de Loecker
January 1982, Recent progress in hormone research,
J P Janssens, and V Noto, and G van Tendeloo, and J Bonte, and W de Loecker
February 1979, Pediatric research,
J P Janssens, and V Noto, and G van Tendeloo, and J Bonte, and W de Loecker
March 1995, Clinical cancer research : an official journal of the American Association for Cancer Research,
J P Janssens, and V Noto, and G van Tendeloo, and J Bonte, and W de Loecker
January 2020, Frontiers in endocrinology,
J P Janssens, and V Noto, and G van Tendeloo, and J Bonte, and W de Loecker
October 1995, Molecular endocrinology (Baltimore, Md.),
Copied contents to your clipboard!